Eton Pharmaceuticals, Inc. (ETON), a commercial-stage pharmaceutical company, Wednesday announced in-licensing of U.S. commercialisation rights to Hemangeo oral solution from Pierre Fabre Medicament SAS, indicated for the treatment of proliferating infantile hemangioma.
Hemangeol oral solution contains the beta-adrenergic blocker propranolol hydrochloride and is approved by the FDA for the treatment of proliferating infantile hemangioma requiring systemic therapy in infants aged between 5 weeks and 5 months. Infantile hemangioma is a bright red birthmark, that looks like a rubbery bump or flat red patch that might have extra blood vessels in the skin.
From May 1, 2026, Eton will commercialise Hemangeol in the U.S. The transaction is expected to be accretive to 2026 earnings and will be financed with the company's cash on hand. Pierre Fabre will continue commercialising Hemangeol globally and in the U.S. until April 30.
Eton plans to administer the Eton Cares patient support program, which provides prescription fulfilment, insurance benefits investigation, educational support, financial assistance for qualified patients, and other services designed to help patients access treatment. In addition, Eton Cares will offer co-pay assistance with a $0 co-pay for qualifying patients.
Sean Brynjelsen, CEO of Eton Pharmaceuticals, said that, as the only treatment for infantile hemangiomas requiring systemic therapy, Hemangeol is a critical medication and a strong fit with Eton's orphan-focused commercial model.
Infantile hemangiomas are non-cancerous vascular tumours which typically appear in the first days or weeks of a newborn's life. Eton estimates that approximately 5,000 to 10,000 infants are treated with Hemangeol annually in the United States.
Including Hemangeol, the company currently has 10 commercial rare disease products: Khindivitm, Increlex, Alkindi Sprinkle, Desmoda, Galzin, Pku Golike, Carglumic Acid, Betaine Anhydrous, and Nitisinone.
Also, Eton has four additional product candidates in late-stage development: Amglidia, ET-700, ET-800 and Zeneo hydrocortisone autoinjector.
In addition, Eton plans to report fourth-quarter and full-year 2025 financial results on Thursday, March 19, 2026. Management will host a conference call and live audio webcast to discuss the results at 4:30 p.m. ET.
ETON has traded between $11.09 and $23.00 in the last year. The stock closed Tuesday's trade at $17.45, down 3.86%.
In the premarket, ETON is down 4.76% at $16.62.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.